Harbor Funds’ mid-cap value team added Regeneron Pharmaceuticals to its portfolio in the second quarter of 2026, citing strong cash flow, earnings potential, and stock buybacks as key reasons for the purchase.
The position was disclosed in the Harbor Mid Cap Value Fund’s Q2 2026 investor letter, which also detailed a blockbuster quarter for global equities. The S&P 500 returned 15.2%, its strongest quarter since 2020, as the artificial intelligence capital spending cycle shifted from software to hardware. Regeneron (NASDAQ:REGN) closed at $827.72 per share on September 4, 2026, giving the biotechnology company a market capitalization of $85.21 billion.
Shares of Regeneron have gained 48.22% over the past 52 weeks and posted a one-month return of 2.43%.
The Fund’s Rationale
Harbor Mid Cap Value Fund said it added to its Regeneron position during the quarter. The fund’s managers said the stock ranks high on multiple cash flow and forecasted earnings measures, which they consider two of the most important valuation metrics.
“We added to our position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotech company in the Health Care sector,” the fund wrote in its Q2 2026 investor letter. “The stock ranks high on multiple cash flow and forecasted earnings measures — two of our most important measures of valuation.”
The fund noted that while Regeneron pays a below-average dividend, the company has been buying back stock, which the managers view positively. Price momentum over the past 12 months has been strong, and the fund pointed to improving operating margins and sales growth as attractive operating momentum indicators.
“Overall, the stock ranks in the top 10% in our stock-ranking universe, which led to the second quarter purchase,” the fund said.
A Strong Quarter for the Fund
The Harbor Mid Cap Value Fund returned 13.99% in Q2 2026, outperforming its benchmark, the Russell Midcap Value Index. Strong stock selection in Consumer Discretionary, Real Estate, and Financials contributed positively to results.
An underweight position in Information Technology negatively impacted returns, however. The sector rose about 33% during the quarter, contributing significantly to the S&P 500’s overall gain.
Small caps outperformed large caps in the quarter. The Russell 2000® gained 21.5%, compared to the Russell 1000’s 15.1%. Growth stocks led within large caps.
“Overall, the stock ranks in the top 10% in our stock-ranking universe, which led to the second quarter purchase.”
Regeneron’s Recent Performance
Regeneron develops and commercializes medicines to treat various diseases. The company’s stock has been on a strong run over the past year.
The fund’s decision to add Regeneron came during a quarter marked by significant economic uncertainty. Despite that, the investment philosophy remains committed to a disciplined value approach, according to the letter.
Hedge fund interest in Regeneron has cooled slightly. According to the source’s database, 63 hedge fund portfolios held Regeneron at the end of the second quarter, down from 72 in the previous quarter.
The AI Alternative
The source publication notes that while Regeneron has potential as an investment, certain AI stocks offer greater upside potential and carry less downside risk. It points to a free report on the best short-term AI stock, which it says stands to benefit from Trump-era tariffs and the onshoring trend.
Regeneron is not on the source’s list of the 40 Most Popular Stocks Among Hedge Funds.
Market Context
The broader market rally in Q2 2026 was driven by a shift in the AI capital spending cycle. Money moved from software to hardware, fueling gains across technology and related sectors.
| Metric | Q2 2026 Result |
|---|---|
| S&P 500 return | 15.2% |
| Russell 2000® return | 21.5% |
| Russell 1000 return | 15.1% |
| Information Technology sector return | ~33% |
| Harbor Mid Cap Value Fund return | 13.99% |
What the Fund Owns
The Harbor Mid Cap Value Fund’s letter highlights Regeneron as a newly added position. The source directs readers to check the fund’s top five holdings for its best picks in 2026.
The fund’s approach centers on finding stocks that rank highly on cash flow and earnings measures. Regeneron’s buyback program and improving margins fit that framework, even with its below-average dividend.
Stock Buyback Appeal
Regeneron’s share repurchase program was a notable factor in the fund’s decision. The fund described the buyback activity positively in its letter, even as it acknowledged the company’s dividend is below average.
A Disciplined Approach
The fund’s managers said they remain committed to their value discipline despite ongoing economic uncertainties. The Q2 letter stated that commitment without making broader claims about the approach’s track record.
The underweight in Information Technology was a drag on performance, but strong stock selection elsewhere offset that shortfall. Consumer Discretionary, Real Estate, and Financials all contributed positively.
The Bottom Line
Harbor’s addition of Regeneron reflects a bet on a biotech company with strong cash flow, solid earnings forecasts, and a shareholder-friendly buyback program. The stock’s 48% gain over the past year suggests momentum is on the fund’s side.
The fund’s outperformance in a strong quarter for markets adds weight to its stock-picking record. Whether Regeneron continues to deliver will depend on its operating margins, sales growth, and the broader biotech market.
For investors watching the mid-cap value space, the Harbor letter offers a clear window into how one fund is positioning for the second half of 2026. Regeneron is now part of that positioning, and the fund’s managers say the stock ranks in the top 10% of their universe.
The question now is whether that ranking holds as the AI-driven market rally evolves and economic uncertainties persist.
Source: finance.yahoo.com
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.